In a study published July 26 online in the journal Diabetes, physician-researchers from University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University School of Medicine, found that the asthma medication montelukast (brand name Singulair), can inhibit early changes in diabetic retinopathy, the eye disease which develops due to diabetes, in a mouse model of type 1 diabetes.
“We found that montelukast (Singulair) was able to disrupt the signaling of inflammatory molecules called leukotrienes. This disruption significantly reduced small blood vessel and nerve damage that we see in the early stages of diabetic retinopathy,” said senior author Rose Gubitosi-Klug, M.D., Ph.D., Chief of Pediatric Endocrinology at UH Rainbow and the William T. Dahms Professor of Pediatrics at CWRU School of Medicine.
More here –> MedicalXpress.com
